Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Toxic Reactions: Overview

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Combinatorial delivery of low-dose radiotherapy and immunotherapy to patients with immune-excluded tumors enhances CD8+ T cell functionality.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8<sup>+</sup> T-myeloid cell networks in melanoma.

Science immunology·2024

Same author

Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.

Clinical cancer research : an official journal of the American Association for Cancer Research·2023

Same author

Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.

Cancer discovery·2021

Same author

A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.

Radiology·2021

Same author

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2020

Same journal

Non-canonical amino acid incorporation enables minimally disruptive labeling of stress granule and TDP-43 proteinopathy.

eLife·2026

Same journal

Analysis of dendritic input currents during place field dynamics.

eLife·2026

Same journal

TopoMetry systematically learns and evaluates the latent geometry of single-cell data.

eLife·2026

Same journal

Navigating the path: Advice to physician-scientists on choosing a clinical specialty.

eLife·2026

Same journal

Neural activity profiles reveal overlapping, intermingled subpopulations spanning area borders in mouse sensorimotor cortex.

eLife·2026

Same journal

The exquisite mechanics of a tsetse bite.

eLife·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Oct 19, 2025

A High-throughput Assay for the Prediction of Chemical Toxicity by Automated Phenotypic Profiling of Caenorhabditis elegans

A High-throughput Assay for the Prediction of Chemical Toxicity by Automated Phenotypic Profiling of Caenorhabditis elegans

Published on: March 14, 2019

A promising platform for predicting toxicity.

Maria Ochoa de Olza¹

¹Lausanne University Hospital, Lausanne, Switzerland.

|September 24, 2021

Summary

This summary is machine-generated.

Organ-on-chip technology offers a promising new way to test cancer immunotherapy drugs for toxicity. This approach could improve how scientists predict potential side effects before human trials.

Keywords:

alveolar biology cancer biology cancer immunotherapy human intestinal biology medicine organs-on-chips preclinical safety t-cell bispecifics

More Related Videos

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox

Published on: August 28, 2019

Related Experiment Videos

Last Updated: Oct 19, 2025

A High-throughput Assay for the Prediction of Chemical Toxicity by Automated Phenotypic Profiling of Caenorhabditis elegans

A High-throughput Assay for the Prediction of Chemical Toxicity by Automated Phenotypic Profiling of Caenorhabditis elegans

Published on: March 14, 2019

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox

Published on: August 28, 2019

Area of Science:

Biomedical Engineering
Pharmacology
Oncology

Background:

Cancer immunotherapies harness the immune system to fight cancer but can cause severe side effects.
Predicting drug toxicity is crucial for patient safety and effective treatment development.
Current toxicity testing methods have limitations in accurately reflecting human responses.

Purpose of the Study:

To evaluate the potential of organ-on-chip technology for predicting cancer immunotherapy drug toxicity.
To explore how microphysiological systems can enhance preclinical safety assessments.

Main Methods:

Utilizing advanced organ-on-chip models that mimic human organ functions.
Testing the toxicological profiles of various cancer immunotherapy agents on these models.

Main Results:

Organ-on-chip systems demonstrated the ability to identify specific toxicities associated with immunotherapies.
Results showed a higher correlation with clinical toxicity data compared to traditional methods.

Conclusions:

Organ-on-chip technology presents a viable and potentially more accurate method for assessing immunotherapy drug safety.
This approach could significantly improve the prediction of adverse events, aiding in the development of safer cancer treatments.